A 6-Week Randomized, Placebo-Controlled Trial of CP-316,311 (a Selective CRH 1 Antagonist) in the Treatment of Major Depression
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The corticotropin-releasing hormone (CRH) system is implicated in the pathogenesis of several psychiatric disorders, including major depressive disorder. This study was designed to evaluate the safety and efficacy of CP-316,311, a selective nonpeptide antagonist of corticotropin-releasing hormone type 1 (CRH(1)) receptors, in the treatment of recurrent major depressive disorder. METHOD: Of a total of 167 patients with recurrent major depression who were screened, 123 were randomly assigned to receive 400 mg of CP-316,311 twice daily, or 100 mg of sertraline daily, or placebo in a 6-week fixed-dose, double-blind, double-dummy, parallel-group, placebo- and sertraline-controlled trial. The primary efficacy analysis compared the change in score from baseline to endpoint on the 17-item Hamilton Depression Rating Scale (HAM-D) between the CP-316,311 and placebo groups. A group sequential design was used to support early trial termination based on efficacy or futility at a planned interim analysis. RESULTS: The evaluable data set for the interim analysis included 28 patients in the CP-316,311 group, 31 patients in the placebo group, and 30 patients in the sertraline group. In the interim analysis, the change from baseline in the HAM-D score at the final visit was not significantly different between the CP-316,311 and placebo groups, while change from baseline between the sertraline and placebo groups was significantly different. Given these results, futility was declared for CP-316,311 and the trial was terminated. CONCLUSIONS: Although CP-316,311 was safe and well tolerated in this study population, it failed to demonstrate efficacy in the treatment of major depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another CRH1 receptor antagonist, CP-316,311, could not achieve a significant improvement of depressive symptoms compared to placebo [102].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [102]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 3×
“tral administration of alpha helical CRH-(9-41), a specific CRH receptor antagonist (4).”
BackgroundMethodDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Physiology and pharmacology of corticotropin-releasing factor.
Owens, M. J., & Nemeroff, C. B. (1991) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06673-6 · Cited by 1,142
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Reduced Corticotropin Releasing Factor Binding Sites in the Frontal Cortex of Suicide Victims
Nemeroff, C. B. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800300075009 · Cited by 555
The Dexamethasone Suppression Test for Diagnosis and Prognosis in Psychiatry: Commentary and Review
Arana, G. W. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790350067012 · Cited by 526
Adrenal Gland Enlargement in Major Depression: A Computed Tomographic Study
Nemeroff, C. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820050048008 · Cited by 283
Nemeroff, C. B., Bissette, G., Akil, H., & Fink, M. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.1.59 · Cited by 254
Research works printed but not linked: 2
- Owens MJ, 1991, Pharmacol Rev, 43, 425
- Shelton RC, 1994, Clin Ther, 16, 768
Cited by
Items 101–200 of 272
Ding, Y., Wei, Z., Yan, H., & Guo, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732157 · Cited by 34
Wolfe, S. A., Sidhu, H., Patel, R. R., Kreifeldt, M., D’Ambrosio, S. R., Contet, C., & Roberto, M. (2019) · eNeuro · doi:10.1523/eneuro.0087-19.2019 · Cited by 36
Gilligan, P. J., He, L., Clarke, T., Tivitmahaisoon, P., Lelas, S., Li, Y.-W., Heman, K. L., Fitzgerald, L. W., Miller, K. J., Zhang, G., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9000242 · Cited by 34
Tellew, J. E., Lanier, M. C., Moorjani, M., Lin, E., Luo, Z., Slee, D. H., Zhang, X., Hoare, S. R. J., Grigoriadis, D. E., St‐Denis, Y., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.095 · Cited by 35
Stress-related depression: Neuroendocrine, genetic, and therapeutical aspects
Bosch, O. G., Seifritz, E., & Wetter, T. C. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.665477 · Cited by 38
“311 failed to show beneficial effects compared to sertraline and placebo (Binneman et al. 2008) and three trials with the progesterone receptor/GR antagonist mifepristone did not show antidepressant effects compared to placebo (Schüle et al.”
BackgroundCortisol, Stress, and Disease—Bidirectional Associations; Role for Corticosteroid-Binding Globulin?
Lee, J. H., Meyer, E. J., Nenke, M. A., Lightman, S. L., & Torpy, D. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae412 · Cited by 41
Hartz, R. A., Ahuja, V. T., Arvanitis, A. G., Rafalski, M., Yue, E. W., Denhart, D. J., Schmitz, W. D., Ditta, J. L., Deskus, J. A., Brenner, A. B., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900301y · Cited by 36
Baumeister, D., Lightman, S. L., & Pariante, C. M. (2016) · Psychopathology Review · doi:10.5127/pr.034413 · Cited by 36
“Moreover, the non-peptide CRH1 antagonist CP-316,311 did not show efficacy as a novel antidepressant when trialled in major depression (Binneman et al., 2008).”
BackgroundGlucocorticoids as Predictors of Treatment Response in Depression
Horstmann, S., & Binder, E. B. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.586550 · Cited by 34
Fronk, G. E., Sant'Ana, S. J. K., Kaye, J. T., & Curtin, J. J. (2020) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-102419-125016 · Cited by 39
“Stress-relevant psychiatric and medical conditions like PTSD and chronic pain are promising moderators given their high comorbidities with SUDs (Ditre et al. 2019, Gilpin &Weiner 2017).”
BackgroundAdvances in novel molecular targets for antidepressants
Wang, Q., & Dwivedi, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110041 · Cited by 34
“Another mGluR2 negative allosteric modulator RG1578 has been tested in MDD patients, however the results are not as promising (Dale et al., 2015).”
ResultInfluentialEmerging drugs for major depressive disorder
Kennedy, S. H., & Rizvi, S. J. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903107751 · Cited by 39
“A subsequent RCT involving CP316311 failed to demonstrate superiority over placebo although there were no safety concerns [133].”
BackgroundThe Tail-Suspension Test: A Model for Characterizing Antidepressant Activity in Mice
O’Leary, O. F., & Cryan, J. F. (2009) · Neuromethods · doi:10.1007/978-1-60761-303-9_7 · Cited by 37
Domin, H., & Śmiałowska, M. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105748 · Cited by 34
Kaye, J. T., Bradford, D. E., Magruder, K. P., & Curtin, J. J. (2017) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2017.78.353 · Cited by 31
“, 2012; Miller, 2010), the previous failures of CRF1 antagonists in phase 3 trials with clinical outcomes for mood and anxiety disorders (Binneman et al., 2008; Coric et al., 2010; but see Koob & Zorrilla, 2012), and practical issues regarding medication availability and public/private funding of future research (see…”
BackgroundSchmidt, M. E., Andrews, R. D., van der Ark, P. D., Brown, T., Mannaert, E., Steckler, T., Hoon, J. N. J. M. D., & Laere, K. V. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1714-1 · Cited by 33
“On the other hand, evaluation of another compound in depressed outpatients, CP-316311, found no evidence of therapeutic benefit on symptoms of depression or anxiety while the positive comparator evinced both ( Binneman et al. 2008 ).”
BackgroundMillion, M., Zhao, J.-F., Luckey, A. E., Czimmer, J., Maynard, G. D., Kehne, J. H., Hoffman, D. C., & Taché, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073749 · Cited by 33
“randomized, placebo-controlled trial [18] and pexacerfont did not”
BackgroundEffect of the CRF1-receptor antagonist pexacerfont on stress-induced eating and food craving
Epstein, D. H., Kennedy, A., Furnari, M. A., Heilig, M. A., Shaham, Y., Phillips, K. A., & Preston, K. L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4424-5 · Cited by 29
“Pexacerfont has been tested in clinical trials for mood and anxiety disorders and was found ineffective for those conditions, though benign in its side-effect profile (Binneman et al. 2008; Coric et al. 2010; Kunzel et al. 2003; Zobel et al. 2000).”
BackgroundSex as a biological variable in stress and mood disorder research
Hodes, G. E., & Kropp, D. R. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00083-3 · Cited by 31
Fernández Macedo, G. V., Cladouchos, M. L., Sifonios, L., Cassanelli, P. M., & Wikinski, S. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2859-x · Cited by 27
“However, the phase II trials that have been performed have failed to reproduce these results (Binneman et al. 2008) indicating that the direct manipulation of CRF/CRF1 signaling would not be efficacious for all patients.”
de la Tremblaye, P. B., & Plamondon, H. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.07.001 · Cited by 28
“A double-blind, placebo-controlled trial of a CRHR1 antagonist (CP-316,211) showed decreased urinary cortisol levels although failed to support antidepressant properties in depressed patients (Binneman et al., 2008).”
BackgroundNeuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets
Herman, F. J., Simkovic, S. J., & Pasinetti, G. M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14569 · Cited by 29
“cant improvements in depressive or anxiety symptomology (Binneman et al., 2008; Coric et al., 2010; Ising et al., 2007).”
BackgroundResultJacobsen, J. P. R., Plenge, P., Sachs, B. D., Pehrson, A. L., Cajina, M., Du, Y., Roberts, W. L., Rudder, M. L., Dalvi, P. H., Robinson, T. J., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3595-1 · Cited by 29
“Regrettably, once promising compounds, such as neuropeptide antagonists (Binneman et al. 2008; Griebel et al. 2012; Keller et al. 2006; Manning et al. 2012; Neurocrine 2013) and selective noradrenaline reuptake inhibitors (Eyding et al. 2010; Michelson et al. 2007; Preti 2002), appear to have…”
BackgroundDong, H., Keegan, J., Hong, E. S., Gallardo, C., Montalvo‐Ortiz, J. L., Wang, B., Rice, K. C., & Csernansky, J. G. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.02.013 · Cited by 28
Advances in the Management of Treatment-Resistant Depression
Holtzheimer, P. E. (2010) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.8.4.foc488 · Cited by 29
Katz, D. A., Liu, W., Locke, C. S., Dutta, S., & Tracy, K. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4089-5 · Cited by 24
“Following 6 weeks of dosing, the CRH1 antagonist CP-316,311 showed a numerical trend for lower morning urine cortisol (Binneman et al. 2008).”
BackgroundOestrogen: an overlooked mediator in the neuropsychopharmacology of treatment response?
Keating, C., Tilbrook, A., & Kulkarni, J. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000982 · Cited by 23
“…from https://academic.oup.com/ijnp/article-abstract/14/4/553/729861 by guest on 26 July 2018 antagonist R121919 in patients, a more recent 6-wk trial of the CRH1 antagonist CP-316,311, showed no positive impact of treatment on symptoms (in males and females) with HAMD scores (Binneman et al. 2008).”
BackgroundChan, I. I., & Wu, A. M. S. (2024) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2024.100294 · Cited by 34
“Our fi ndings also clarify that, contrary to one previous MR study (22) but consistent with another MR study (23), RCTs of CRF1 antagonists (15) and previous observational studies on personality (63), cortisol was not associated with major depression or neuroticism.”
MethodResultSaito, T., Obitsu, T., Kondo, T., Matsui, T., Nagao, Y., Kusumi, K., Matsumura, N., Ueno, S., Kishi, A., Katsumata, S., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.07.055 · Cited by 23
Cannella, N., Ubaldi, M., Masi, A., Bramucci, M., Roberto, M., Bifone, A., & Ciccocioppo, R. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.05.014 · Cited by 25
Chapter 1 Recent Advances in Corticotropin-Releasing Factor Receptor Antagonists
Dzierba, C. D., Hartz, R. A., & Bronson, J. J. (2008) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)00001-8 · Cited by 22
Steckler, T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_14 · Cited by 22
“More recently, however, lack of efficacy was reported for the CRF1 antagonist CP-316,311 in a 6-week randomized, placebo controlled trial in depressed patients, which used the Hamilton Depression scale as a primary endpoint but also included a secondary efficacy analysis on the Hamilton Anxiety Scale (HAM-A) ( Binnema…”
MethodTranslating depression biomarkers for improved targeted therapies
Bredt, D. S., Furey, M. L., Chen, G., Lovenberg, T., Drevets, W. C., & Manji, H. K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.013 · Cited by 23
Gutman, D. A., Owens, M. J., Thrivikraman, K. V., & Nemeroff, C. B. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.004 · Cited by 23
“A later clinical studywith the CRF1 receptor antagonist CP-316,311was terminated early due to lack of efficacy of this compound in the treatment of major depression (Binneman et al., 2008).”
Wiersielis, K., Ceretti, A., Hall, A., Famularo, S. T., Salvatore, M., Ellis, A. S., Jang, H., Wimmer, M. E., & Bangasser, D. A. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100150 · Cited by 21
“…of these drugs for treating disorders, such as depression, generalized anxiety disorder, and posttraumatic stress disorder, only in females or in both sexes with male and female data combined for analysis (Binneman et al., 2008; Coric et al., 2010; Dunlop et al., 2017; Howerton et al., 2014).”
BackgroundEmerging drugs for bipolar disorder
Sanches, M., Newberg, A. B., & Soares, J. C. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.492393 · Cited by 21
“However, a recent randomized, doubleblind trial did not find evidence of antidepressant effects of another of these drugs in major depression [80].”
BackgroundLeszczyńska-Rodziewicz, A., Szczepankiewicz, A., Dmitrzak-Węglarz, M., Skibińska, M., & Hauser, J. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.025 · Cited by 19
“In the treatment of mood symptoms drugs targeting CRHR-1-receptor (antagonists) and vasopressin-1b-receptor (antagonists), were also examined (Binneman et al., 2008; Holsboer and Ising, 2008), as well as the application of GR antagonists (Pomara et al., 2002).”
Mantsch, J. R. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100038 · Cited by 25
“These outcomes are consistent with those from clinical trials investigating the efficacy of CRF receptor antagonists in individuals with generalized anxiety disorder [349], major depression [350]; GlaxoSmithKline, CRS106139), or PTSD [351].”
ResultLuo, X., Zhu, D., Li, J., Ren, M., Liu, Y., Si, T., & Chen, Y. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115391 · Cited by 22
Namiot, E. D., Smirnovová, D., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03031-6 · Cited by 27
Development of New Psychopharmacological Agents for Depression and Anxiety
Schatzberg, A. F. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.05.009 · Cited by 19
Mochizuki, M., Kori, M., Kobayashi, K., Yano, T., Sako, Y., Tanaka, M., Kanzaki, N., Gyorkos, A. C., Corrette, C. P., Cho, S. Y., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01715 · Cited by 20
Toward Personalized Medicine in the Neuropsychiatric Field
Wong, E. H. F., Fox, J. C., Ng, M., & Lee, C. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-387718-5.00013-4 · Cited by 21
Miller, S., & Maguire, J. L. (2014) · Hormonal Studies · doi:10.7243/2052-8000-2-2 · Cited by 20
“In addition, more recently, another CRH receptor antagonist, CP-316,311, also underwent clinical trial, and although it was safe and well tolerated, it failed to decrease depression symptoms [81].”
BackgroundSaito, T., Obitsu, T., Kohno, H., Sugimoto, I., Matsushita, T., Nishiyama, T., Hirota, T., Takeda, H., Matsumura, N., Ueno, S., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.11.015 · Cited by 18
Torres-Reverón, A., Rivera-López, L. L., Flores, I., & Appleyard, C. B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197698 · Cited by 19
Silberman, Y., Fetterly, T. L., Awad, E. K., Milano, E. J., Usdin, T. B., & Winder, D. G. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12881 · Cited by 19
Takahashi, Y., Hashizume, M., Shin, K., Terauchi, T., Takeda, K., Hibi, S., Murata-Tai, K., Fujisawa, M., Shikata, K., Taguchi, R., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300864p · Cited by 20
Chaki, S., Shimazaki, T., Nishiguchi, M., Funakoshi, T., Iijima, M., Ito, A., Kanuma, K., & Sekiguchi, Y. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.05.018 · Cited by 19
Heilig, M. A. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13636 · Cited by 20
“However, in parallel with these results, CRF1 antagonists failed on other stress-related psychiatric indications [85– 87].”
ResultTanahashi, S., Yamamura, S., Nakagawa, M., Motomura, E., & Okada, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2506-y · Cited by 21
“Despite these findings in animal models, a recent double-blind placebo-controlled trial failed to detect any antidepressant action for CRF1 receptor antagonist (CP-316,211) in depressed patients (Binneman et al. 2008).”
ResultVasiliu, O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884155 · Cited by 22
“The response rate was the same in all three groups Phase IIa, NCT01145755 AE, adverse events; AMPA, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; BD, bipolar depression; BDI, Beck Depression Inventory; BDM, Bipolar Inventory of Symptoms Scale-derived MADRS; BDNF, brain-derived neurotrophic factor; CANTAB,…”
BackgroundMethodResultInfluentialCorticotropin-releasing factor 1 receptor antagonists: a patent review
Williams, J. P. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.795545 · Cited by 17
“Nearly 30 years after CRF was isolated, Pfizer reported a placebo-controlled study in patients with major depressive disorder with the CRF1 antagonist CP-316,311 (4) [13].”
BackgroundOhmura, Y., & Yoshioka, M. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824679 · Cited by 17
“Lastly, a CRF1 receptor antagonist did not produce antidepressant effects in a double-blinded clinical trial with a relatively large sample size [140], while the antidepressant effects of another CRF1 receptor antagonist were found in a small sample size [141].”
BackgroundAre mGluR2/3 Inhibitors Potential Compounds for Novel Antidepressants?
Yajie, J., Zou, M., Ren, T., & Wang, Y. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01310-8 · Cited by 14
Hodgetts, K. J., Ge, P., Yoon, T., Lombaert, S. D., Brodbeck, R. M., Gulianello, M., Kieltyka, A., Horvath, R. F., Kehne, J. H., Krause, J. E., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200365y · Cited by 15
Nicholson, J. R., & Sommer, B. (2018) · Brain and Neuroscience Advances · doi:10.1177/2398212818804030 · Cited by 15
Curley, D. E., Webb, A. E., Sheffler, D. J., & Haass‐Koffler, C. L. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.786855 · Cited by 14
Ritchie, J. L., Walters, J. L., Galliou, J. M., Christian, R. J., Qi, S., Savenkova, M. I., Ibarra, C. K., Grogan, S. R., & Fuchs, R. A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108819 · Cited by 13
Devetzis, V., Zarogoulidis, P., Kakolyris, S., Vargemezis, V. A., & Chatzaki, Ε. (2012) · Medicinal Research Reviews · doi:10.1002/med.21268 · Cited by 12
Plag, J., Schumacher, S., Schmid, U., & Ströhle, A. (2013) · Neuropsychiatry · doi:10.2217/npy.13.6 · Cited by 17
Ballenger, J. C. (2009) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)79165-5 · Cited by 12
Genetic Dissection of the Neuroendocrine and Behavioral Responses to Stressful Challenges
Chen, A. (2016) · Research and perspectives in endocrine interactions · doi:10.1007/978-3-319-41603-8_6 · Cited by 14
“…1987; Dunn and Berridge 1990) or its overexpression in transgenic mice (Stenzel-Poore et al. 1994; Heinrichs et al. 1997; van Gaalen et al. 2002; Binneman et al. 2008)] produces anxiogenic behavior, whereas suppression induces anxiolytic effects (Skutella et al. 1994) and reduced stress-induced…”
BackgroundDie Zukunft der Depressionsforschung
Holsboer, F. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-3053-1 · Cited by 13
Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial level
Guizzaro, L., Morgan, D. D. V., Falco, A., & Gallo, C. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.04.022 · Cited by 11
Lee, M. R., Rio, D. E., Kwako, L. E., George, D. T., Heilig, M. A., & Momenan, R. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01521-z · Cited by 12
HPA axis function in mood disorders
Watson, S., & Mackin, P. (2009) · Psychiatry · doi:10.1016/j.mppsy.2008.11.006 · Cited by 17
Biological Theories of Depression and Implications for Current and New Treatments
GOLDSTEIN, D. J., Potter, W. Z., Ciraulo, D. A., & Shader, R. I. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-435-7_1 · Cited by 12
Wilhelm, C., Murphy-Crews, A., Menasco, D., Huckans, M. S., & Loftis, J. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.040 · Cited by 9
“Subsequent studies in humans, however, indicate that CRF1 antagonism may have limited efficacy as an antidepressant (e.g. Binneman et al. 2008).”
BackgroundNeuroregulatory Peptides of Central Nervous System Origin: From Laboratory to Clinic
Geracioti, T. D., Strawn, J. R., Ekhator, N. N., Wortman, M. D., & Kasckow, J. W. (2009) · Elsevier eBooks · doi:10.1016/b978-008088783-8.00082-6 · Cited by 13
Emerging drugs for major depressive disorder: an update
Rizvi, S. J., & Kennedy, S. H. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.681301 · Cited by 12
Taguchi, R., Shikata, K., Furuya, Y., Ino, M., Shin, K., & Shibata, H. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.017 · Cited by 9
Takeda, K., Terauchi, T., Hashizume, M., Shin, K., Ino, M., Shibata, H., & Yonaga, M. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.07.047 · Cited by 8
Yang, X., & Geng, F. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25238 · Cited by 11
Aso, K., Kobayashi, K., Mochizuki, M., Kanzaki, N., Sako, Y., & Yano, T. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.02.086 · Cited by 8
Takeda, K., Terauchi, T., Hashizume, M., Shikata, K., Taguchi, R., Murata-Tai, K., Fujisawa, M., Takahashi, Y., Shin, K., Ino, M., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.09.028 · Cited by 8
Tiwari, M. N., Mohan, S., Biala, Y., Shor, O., Benninger, F., & Yaari, Y. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.2475-21.2022 · Cited by 8
Translational Approaches to Medication Development
Bartlett, S. E., & Heilig, M. A. (2011) · Current topics in behavioral neurosciences · doi:10.1007/978-3-642-28720-6_132 · Cited by 8
Synthesis of 3,4-dihydropyrimido[1,2-a]benzimidazoles, promising CRF1 receptor antagonists
Vandyshev, D. Y., Kovygin, Y. A., Khmelevskaya, T. N., Scherbakov, K. A., Шихалиева, К. Д., Smoliannikova, M. Y., & Shikhaliev, K. S. (2024) · Russian Chemical Bulletin · doi:10.1007/s11172-024-4213-y · Cited by 8
Takeda, K., Terauchi, T., Shin, K., Ino, M., Shibata, H., & Yonaga, M. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.066 · Cited by 8
Weisler, R. H., McIntyre, R. S., & Bauer, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.846519 · Cited by 8
Zimmerman, M., Multach, M. D., Walsh, E. K., Rosenstein, L. K., Gazarian, D., & Clark, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0314-y · Cited by 8
Hormone circuit explains why most HPA drugs fail for mood disorders and predicts the few that work
Milo, T., Halber, S. N., Raz, M., Danan, D., Mayo, A., & Alon, U. S. (2025) · Molecular Systems Biology · doi:10.1038/s44320-024-00083-0 · Cited by 8
Gehlert, D. R., Cramer, J. W., & Morin, S. M. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189753 · Cited by 6
“, 2010) or antidepressant (Binneman et al., 2008) activities.”
Ahuja, V. T., Hartz, R. A., Molski, T. F. P., Mattson, G. K., Lentz, K. A., Grace, J. E., Lodge, N. J., Bronson, J. J., & Macor, J. E. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.067 · Cited by 6
Hupalo, S., Spencer, R. C., & Berridge, C. W. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15260 · Cited by 6
Berger, T., van Calker, D., Brakemeier, E., & Schramm, E. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-22485-0.00011-7 · Cited by 9
CRF1 receptor antagonists: treatment of stress-related disorders
Kehne, J. H., & Maynard, G. D. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.09.003 · Cited by 6
Majeed, M. W., Finnegan, E. A., Ruelas, M. G., Quirós, M., da Silva, M. B., Salha, I., Herrán-Fonseca, C., de Oliveira, H. M., Quirós, M. C., Ahmed, R., et al. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100247 · Cited by 5
What future for neuroendocrinology in psychiatry?
Duval, F., Mokrani, M., & Crocq, M. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.04.012 · Cited by 6
“…CRH1 receptors), which are still under development, may lead to new opportunities in the treatment of affective disorders by rectifying HPA disturbances (Ising and Holsboer, 2007), although, the only controlled study investigating a CRH1 receptor antagonist was negative (Binneman et al., 2008).”
Mochizuki, M., Kojima, T., Kobayashi, K., Kotani, E., Ishichi, Y., Kanzaki, N., Nakagawa, H., Okuda, T., Kosugi, Y., Yano, T., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.011 · Cited by 6
Donaldson, A. M., Gonzalez, J. G., Parmar, M., & Donaldson, N. (2009) · International Journal of Surgery · doi:10.1016/j.ijsu.2009.04.017 · Cited by 4
Modulation of HPA Axis Function for Treatment of Mood Disorders
Brothers, S. P., Wahlestedt, C., & Nemeroff, C. B. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00276 · Cited by 4
Park, D., Lee, G., Kim, B. S., Seong, M., & Kim, J. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02288-9 · Cited by 4
Endocrinological Treatment Targets for Depressive Disorder
Yoon, S., & Kim, Y. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_1 · Cited by 3
Berger, T., van Calker, D., Brakemeier, E., & Schramm, E. (2009) · Elsevier eBooks · doi:10.1016/b978-343722481-2.50015-5 · Cited by 8
Mueller, L. E., Wexler, R. S., Lovejoy, D. A., Stein, R. B., & Slee, A. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06582-0 · Cited by 4
“Specifically, in one human trial it was shown that despite receptor antagonism made evident by decreased cortisol levels, a CRF 1 receptor antagonist had no behavioral effect on major depressive disorder (Binneman et al. 2008).”
BackgroundQuiroz, J. A., Chen, G., Drevets, W. C., Henter, I. D., & Manji, H. K. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.004 · Cited by 5
Anxiety and depression: leading edge of therapy
Mathew, S. J., & Charney, D. S. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20049 · Cited by 3
Goldberg, J. F., & Rush, A. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363178 · Cited by 4
Metadata
- Authors
- Binneman, B., Feltner, D., Kolluri, S., Shi, Y., Qiu, R., & Stiger, T.
- Affiliations
- Pfizer (United States) (US)
- ORCID
- Qiu, Ruolun
- Venue
- American Journal of Psychiatry
- Published
- 2008-05
- Volume
- 165
- Issue
- 5
- Pages
- 617-620
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2129752568
- Cited by
- 254
- References
- 13
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 9 · 2021: 7 · 2020: 7 · 2019: 13 · 2018: 10 · 2017: 8 · 2016: 19 · 2015: 13 · 2014: 14 · 2013: 16 · 2012: 21
- FWCI
- 22.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- corticotropin-releasing factor, major depressive disorder, recurrent depression, sertraline, antidepressant efficacy, drug safety and tolerability, futility, interim analysis, group sequential designs
- MeSH terms
- CRF Receptor, Type 1, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Humans, Middle Aged, Surveys and Questionnaires, Treatment Outcome, Receptors, Corticotropin-Releasing Hormone, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.